ECSP22010228A - Conjugados peptídicos de citotoxinas como terapéuticos - Google Patents
Conjugados peptídicos de citotoxinas como terapéuticosInfo
- Publication number
- ECSP22010228A ECSP22010228A ECSENADI202210228A ECDI202210228A ECSP22010228A EC SP22010228 A ECSP22010228 A EC SP22010228A EC SENADI202210228 A ECSENADI202210228 A EC SENADI202210228A EC DI202210228 A ECDI202210228 A EC DI202210228A EC SP22010228 A ECSP22010228 A EC SP22010228A
- Authority
- EC
- Ecuador
- Prior art keywords
- cytotoxins
- therapeutics
- peptide conjugates
- conjugates
- peptide
- Prior art date
Links
- 231100000599 cytotoxic agent Toxicity 0.000 title abstract 2
- 239000002619 cytotoxin Substances 0.000 title abstract 2
- 239000000863 peptide conjugate Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La presente invención se refiere a conjugados peptídicos de citotoxinas tales como inhibidores de topoisomerasa I que son útiles para el tratamiento de enfermedades tal como cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962872643P | 2019-07-10 | 2019-07-10 | |
US202063040859P | 2020-06-18 | 2020-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22010228A true ECSP22010228A (es) | 2022-05-31 |
Family
ID=71787212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202210228A ECSP22010228A (es) | 2019-07-10 | 2022-02-09 | Conjugados peptídicos de citotoxinas como terapéuticos |
Country Status (17)
Country | Link |
---|---|
US (2) | US11634508B2 (es) |
EP (1) | EP3997093A1 (es) |
JP (1) | JP2022541749A (es) |
KR (1) | KR20220052918A (es) |
CN (1) | CN114341162A (es) |
AU (1) | AU2020309570A1 (es) |
BR (1) | BR112022000337A2 (es) |
CA (1) | CA3146560A1 (es) |
CL (1) | CL2022000038A1 (es) |
CO (1) | CO2022001316A2 (es) |
CR (1) | CR20220058A (es) |
EC (1) | ECSP22010228A (es) |
IL (1) | IL289658A (es) |
MX (1) | MX2022000449A (es) |
PE (1) | PE20220563A1 (es) |
TW (1) | TW202116778A (es) |
WO (1) | WO2021007435A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3146385A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
TW202214230A (zh) | 2020-09-30 | 2022-04-16 | 大陸商映恩生物製藥(蘇州)有限公司 | 一種抗腫瘤化合物及其製備方法和應用 |
JP2024503380A (ja) | 2021-01-08 | 2024-01-25 | サイブレクサ 2,インコーポレイテッド | コンジュゲート連結部分を調製するための方法 |
EP4329817A1 (en) | 2021-04-29 | 2024-03-06 | Cybrexa 2, Inc. | Dosing regimens of peptide conjugates of topoisomerase i inhibitors |
US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
US20230416331A1 (en) * | 2021-11-17 | 2023-12-28 | Cybrexa 4, Inc. | Peptide conjugates of peptidic tubulin inhibitors as therapeutics |
TW202342025A (zh) * | 2022-03-18 | 2023-11-01 | 大陸商映恩生物製藥(蘇州)有限公司 | Gpc3抗體藥物偶聯物及其用途 |
KR20230141412A (ko) * | 2022-03-29 | 2023-10-10 | 주식회사 퓨전바이오텍 | 친수성 펩타이드를 포함하는 마이셀 및 이의 용도 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
DK0841924T3 (da) | 1995-08-02 | 2003-02-10 | Univ Newcastle Ventures Ltd | Benzimidazolforbindelser |
KR20000064811A (ko) | 1996-04-26 | 2000-11-06 | 스즈키 다다시 | 테트라히드로인돌리진 유도체의 제조법 |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
IN189180B (es) | 1997-07-09 | 2003-01-04 | Chong Kun Dang Corp | |
JP4560210B2 (ja) | 1998-05-22 | 2010-10-13 | 第一三共株式会社 | 薬物複合体 |
EP1619210A1 (en) | 1998-10-30 | 2006-01-25 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
ATE284392T1 (de) | 1998-11-03 | 2004-12-15 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
ES2218110T3 (es) | 1999-01-11 | 2004-11-16 | Agouron Pharmaceuticals, Inc. | Inhibidores triciclicos de poli(adp-ribosa)polimerasas. |
DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
US6699876B2 (en) | 1999-11-18 | 2004-03-02 | Les Laboratoires Servier | Camptothecin analogue compounds |
AU3071801A (en) | 1999-12-13 | 2001-06-18 | Eli Lilly And Company | Pseudomycin phosphate prodrugs |
BR0112417A (pt) | 2000-07-13 | 2003-07-01 | Daiichi Seiyaku Co | Composições farmacêuticas contendo composto dds |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
CN102133407A (zh) | 2002-03-01 | 2011-07-27 | 图兰恩教育基金管理人 | 治疗剂或细胞毒性剂与生物活性肽的偶联物 |
JP4359150B2 (ja) | 2002-03-20 | 2009-11-04 | ブリストル−マイヤーズ スクイブ カンパニー | フルオロオキシインドールのホスフェートプロドラッグ |
CA2482806A1 (en) | 2002-04-30 | 2003-11-13 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
EP1611137A1 (en) | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
WO2004110498A2 (en) | 2003-05-14 | 2004-12-23 | Immunogen, Inc. | Drug conjugate composition |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
BRPI0410748B8 (pt) | 2003-05-20 | 2021-05-25 | Immunogen Inc | compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
JP5466814B2 (ja) | 2003-07-25 | 2014-04-09 | カンサー リサーチ テクノロジー リミテッド | 治療用化合物 |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
HUE025996T2 (en) | 2003-12-01 | 2016-05-30 | Kudos Pharm Ltd | Inhibitors of DNA damage repair for the treatment of cancer |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP1789391B1 (en) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
EP1793830A2 (en) | 2004-09-22 | 2007-06-13 | Pfizer, Inc. | Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
CA2580833C (en) | 2004-09-22 | 2010-12-21 | Pfizer, Inc. | Method of preparing poly(adp-ribose) polymerases inhibitors |
AU2005286191B2 (en) | 2004-09-22 | 2011-11-17 | Cancer Research Technology Ltd. | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
CA2591148A1 (en) | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
WO2006078816A2 (en) | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
US7301019B2 (en) | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
AU2006213662B2 (en) | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
KR20070120156A (ko) | 2005-04-15 | 2007-12-21 | 이뮤노젠 아이엔씨 | 종양에서 이종 또는 혼성 세포 집단의 제거 방법 |
NZ609752A (en) | 2005-08-24 | 2014-08-29 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
CN101316834A (zh) | 2005-09-29 | 2008-12-03 | 艾博特公司 | 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂 |
ATE540956T1 (de) | 2005-11-08 | 2012-01-15 | Immunogen Inc | Verfahren zur herstellung von maytansinol |
SI2338487T1 (sl) | 2006-01-17 | 2014-01-31 | Abbott Laboratories | Kombinacijska terapija z inhibitorji PARP |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
AU2008204380B2 (en) | 2007-01-10 | 2013-08-15 | Msd Italia S.R.L. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
WO2008114114A2 (en) | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
WO2009002993A1 (en) * | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
HUE047200T2 (hu) * | 2007-08-17 | 2020-04-28 | Purdue Research Foundation | PSMA kötõ ligandum-linker konjugátumok és azok alkalmazási módszerei |
BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
LT2437790T (lt) | 2009-06-03 | 2019-06-10 | Immunogen, Inc. | Konjugavimo būdai |
US9353140B2 (en) | 2009-11-25 | 2016-05-31 | Academia Sinica | BQC-G, a tumor-selective anti-cancer prodrug |
SG10201406805RA (en) | 2010-02-12 | 2014-11-27 | Pfizer | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
CA2790577A1 (en) * | 2010-02-25 | 2011-09-01 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
SG184323A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasett Llc | Stereoselective synthesis of phosphorus containing actives |
US8754190B2 (en) | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
US9289508B2 (en) | 2010-07-13 | 2016-03-22 | University Of Rhode Island | Environmentally sensitive compositions and methods of use in the treatment and diagnosis of tumors |
AU2011289279B2 (en) | 2010-08-13 | 2016-11-03 | University Of Rhode Island Board Of Trustees | Liposome compositions and methods of use thereof |
CN103269712B (zh) | 2010-11-03 | 2016-09-21 | 伊缪诺金公司 | 包含新型安丝菌素衍生物的细胞毒性剂 |
KR20220009505A (ko) | 2011-03-29 | 2022-01-24 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
WO2012135522A2 (en) | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Process for manufacturing conjugates of improved homogeneity |
KR101877598B1 (ko) | 2011-10-14 | 2018-07-11 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
KR20230142808A (ko) | 2012-10-11 | 2023-10-11 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
ES2782248T3 (es) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
WO2014066002A1 (en) * | 2012-10-23 | 2014-05-01 | The Johns Hopkins University | Novel self-assembling drug amphiphiles and methods for synthesis and use |
WO2014093343A2 (en) | 2012-12-10 | 2014-06-19 | Massachusetts Institute Of Technology | Multistage nanoparticle drug delivery system for the treatment of solid tumors |
WO2014134483A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
WO2015095755A1 (en) | 2013-12-19 | 2015-06-25 | Seattle Genetics, Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
EP3094752A4 (en) | 2014-01-16 | 2017-08-16 | Clovis Oncology, Inc. | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity |
JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗cd98抗体−薬物コンジュゲート |
MY195180A (en) | 2014-04-10 | 2023-01-11 | U3 Pharma Gmbh | Anti-HER3 Antibody-Drug Conjugate |
WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
WO2016028689A1 (en) | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | High dosage strength tablets of rucaparib |
PL3110447T3 (pl) | 2014-09-16 | 2020-10-19 | Synermore Biologics Co., Ltd. | Przeciwciało anty-EGFR i jego zastosowania |
RU2711930C2 (ru) | 2014-11-19 | 2020-01-23 | Иммуноджен, Инк. | Способ получения конъюгатов агента, связывающегося с клетками, и цитотоксического агента |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
EP3380486B1 (en) | 2015-11-24 | 2020-02-19 | Theravance Biopharma R&D IP, LLC | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
KR102498258B1 (ko) | 2016-01-20 | 2023-02-10 | 삼성디스플레이 주식회사 | 표시 장치 |
US20170267727A1 (en) | 2016-03-04 | 2017-09-21 | Lehigh University | Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors |
EP3426301A4 (en) | 2016-03-08 | 2019-11-06 | Los Gatos Pharmaceuticals, Inc. | VERBUNDNANOPARTICLES AND USES THEREOF |
EP3442592A4 (en) * | 2016-04-13 | 2019-11-27 | Tarveda Therapeutics, Inc. | NEUROTENSIN RECEPTOR BINDING CONJUGATES AND ASSOCIATED FORMULATIONS |
GB201608885D0 (en) | 2016-05-20 | 2016-07-06 | Univ Birmingham | Treatment |
WO2017210608A1 (en) | 2016-06-02 | 2017-12-07 | Yale University | Compositions and methods for targeting and treating homologous recombination-deficient tumors |
EP3491007A4 (en) | 2016-07-29 | 2020-04-22 | Memorial Sloan-Kettering Cancer Center | RADIO-MARKED LIGANDS FOR TARGETED PET / SPECT IMAGING AND METHODS OF USE THEREOF |
IL264845B2 (en) | 2016-08-16 | 2023-09-01 | Aist | Peptides targeting malignant tumors, conjugates and preparations containing them and their uses |
EP3515927A4 (en) | 2016-09-22 | 2020-06-24 | Rhode Island Council on Postsecondary Education | FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A PH TRIGGERED POLYPEPTIDE |
WO2018227132A1 (en) | 2017-06-09 | 2018-12-13 | Rhode Island Council On Postsecondary Education | Linked and other ph-triggered compounds |
JP7248578B2 (ja) | 2017-08-31 | 2023-03-29 | 第一三共株式会社 | 抗体-薬物コンジュゲートの新規製造方法 |
CN111989137A (zh) | 2018-01-05 | 2020-11-24 | 赛博克萨1公司 | 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法 |
US20200360545A1 (en) | 2018-01-12 | 2020-11-19 | Prolynx Llc | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
EP4249002A3 (en) | 2018-05-18 | 2023-11-22 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
TW202015740A (zh) | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | 喜樹鹼結合物 |
CN109232719B (zh) | 2018-09-21 | 2021-06-29 | 中国科学院理化技术研究所 | 一种pH响应的抗菌肽及其制备方法和应用 |
CN114158253A (zh) | 2019-01-28 | 2022-03-08 | 罗德岛大学理事会 | 强效细胞毒性化合物的pHLIP®靶向递送 |
PL3946464T3 (pl) | 2019-03-29 | 2022-12-19 | Medimmune Limited | Związki i ich koniugaty |
CA3146385A1 (en) | 2019-07-10 | 2021-01-14 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
-
2020
- 2020-07-09 CN CN202080057842.4A patent/CN114341162A/zh active Pending
- 2020-07-09 CA CA3146560A patent/CA3146560A1/en active Pending
- 2020-07-09 KR KR1020227004522A patent/KR20220052918A/ko unknown
- 2020-07-09 CR CR20220058A patent/CR20220058A/es unknown
- 2020-07-09 US US16/925,094 patent/US11634508B2/en active Active
- 2020-07-09 TW TW109123269A patent/TW202116778A/zh unknown
- 2020-07-09 EP EP20746521.2A patent/EP3997093A1/en active Pending
- 2020-07-09 PE PE2022000039A patent/PE20220563A1/es unknown
- 2020-07-09 BR BR112022000337A patent/BR112022000337A2/pt unknown
- 2020-07-09 WO PCT/US2020/041411 patent/WO2021007435A1/en unknown
- 2020-07-09 AU AU2020309570A patent/AU2020309570A1/en active Pending
- 2020-07-09 MX MX2022000449A patent/MX2022000449A/es unknown
- 2020-07-09 JP JP2022501188A patent/JP2022541749A/ja active Pending
-
2022
- 2022-01-06 IL IL289658A patent/IL289658A/en unknown
- 2022-01-06 CL CL2022000038A patent/CL2022000038A1/es unknown
- 2022-02-09 EC ECSENADI202210228A patent/ECSP22010228A/es unknown
- 2022-02-09 CO CONC2022/0001316A patent/CO2022001316A2/es unknown
-
2023
- 2023-02-27 US US18/174,981 patent/US20240010755A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11634508B2 (en) | 2023-04-25 |
PE20220563A1 (es) | 2022-04-13 |
AU2020309570A1 (en) | 2022-02-03 |
CO2022001316A2 (es) | 2022-05-10 |
TW202116778A (zh) | 2021-05-01 |
KR20220052918A (ko) | 2022-04-28 |
EP3997093A1 (en) | 2022-05-18 |
CR20220058A (es) | 2022-07-19 |
MX2022000449A (es) | 2022-04-25 |
BR112022000337A2 (pt) | 2022-04-12 |
IL289658A (en) | 2022-03-01 |
CA3146560A1 (en) | 2021-01-14 |
WO2021007435A1 (en) | 2021-01-14 |
CL2022000038A1 (es) | 2022-08-19 |
JP2022541749A (ja) | 2022-09-27 |
US20240010755A1 (en) | 2024-01-11 |
CN114341162A (zh) | 2022-04-12 |
US20210009719A1 (en) | 2021-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022001316A2 (es) | Conjugados peptídicos de citotoxinas como terapéuticos | |
ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
CO2020013599A2 (es) | Piridazinonas como inhibidoras de parp7 | |
ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
CO2022004694A2 (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
ECSP17062716A (es) | Heterociclos bicíclicos como inhibidores de fgfr4 | |
ECSP20060827A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
ECSP16073171A (es) | Ciclopropilaminas como inhibidores de lsd1 | |
CO2017011484A2 (es) | Inhibidores de bromodominio | |
ECSP16073190A (es) | Ciclopropilaminas como inhibidores de lsd1 | |
BR112021024236A2 (pt) | Proteínas multiespecíficas | |
CO2022001315A2 (es) | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos | |
ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
MX2020003862A (es) | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). | |
CO2017005566A2 (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis | |
CL2022000457A1 (es) | Triazolopirimidinas como inhibidores de a2a/a2b. | |
NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
ECSP20082988A (es) | Agonistas de tlr7 | |
ECSP15001225A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos | |
CR20140577A (es) | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |